Danaher Q3 2026 Earnings: Core Growth Accelerates as Bioprocessing Orders Build

Danaher reported third-quarter revenue of $6.6B, up 8.5% year over year, while GAAP diluted EPS from continuing operations rose 34.5% to $1.71. Adjusted diluted EPS increased 11.5% to $2.11, and core revenue growth excluding respiratory testing accelerated to 5.5% from 4.5% in the second quarter.

The quarter was broadly stronger, supported by improving bioprocessing demand, healthier biotech activity, and continued momentum in Diagnostics outside respiratory testing. The more important question is whether Danaher can sustain mid-single-digit organic growth while converting its improving order trends, broader commercial coordination, and recent acquisitions into durable share gains.

Earnings Snapshot

The Bigger Story

Danaher’s quarter points to a gradual recovery in its core life-sciences and biotechnology markets rather than a broad-based surge in demand. Excluding respiratory testing, organic growth reached 5.5%, led by 5% growth in Biotechnology and 7% growth in Diagnostics excluding respiratory revenue.

The company’s strategic focus is also shifting. New CEO Julie Sawyer Montgomery said Danaher has largely completed its portfolio transformation and is now concentrating on extracting more growth from the businesses it owns. Her near-term emphasis is commercial execution, particularly coordinated selling across Danaher’s operating companies to increase customer share of wallet.

Management said this more connected approach has created “several hundred millions of dollars” in revenue opportunities within Diagnostics. Those opportunities are not reported revenue, and their conversion will be an important measure of whether the strategy can produce the consistent share gains management is targeting.

Revenue and Operating Performance

Reported revenue increased 8.5% to $6.6B, but the underlying growth rate was lower. Acquisitions and divestitures contributed 6.5 percentage points to reported sales growth, while tariff refunds to customers contributed another percentage point. After adjusting for these factors and currency, core revenue increased 3%.

Respiratory testing remained the principal drag on comparable growth. Respiratory revenue was approximately $350M in the quarter, down from the prior-year period because of lower global infection rates. This represented a 250-basis-point headwind to total company core growth and a much larger 650-basis-point headwind in Diagnostics.

Biotechnology: Improving orders support the recovery case

Biotechnology core revenue grew 5%, with bioprocessing sales rising toward the upper end of the mid-single-digit range. Consumables increased mid-single digits, led by upstream consumables, while equipment sales rose low single digits.

More notably, bioprocessing orders increased in the mid-teens, with strength in upstream consumables and resins. Management said both equipment and consumables orders have increased solidly year to date, supporting a growing backlog. This order trajectory is encouraging because it suggests customer production activity and new program activity are improving, but the pace at which orders convert into revenue will determine the strength of the 2027 growth outlook.

Discovery and medical revenue declined low single digits. Growth in protein research instrumentation was more than offset by timing effects and weaker lab consumables demand.

Life Sciences: Recovery remains gradual

Life Sciences core revenue rose 4.5%, extending a recovery that management said has exceeded its internal expectations for three consecutive quarters.

Pall’s applied filtration business grew mid-single digits, supported by aerospace and microelectronics. Life Sciences instruments also rose mid-single digits, led by SCIEX, where pharma and biopharma demand remained strong and U.S. academic spending improved modestly.

Consumables growth was more subdued at low single digits. IDT benefited from momentum in minimal residual disease and next-generation sequencing, while Abcam saw improved academic demand and progress in commercial initiatives aimed at pharma and biopharma customers.

Management described large pharma and biopharma demand as robust, while biotech funding continued to improve. Academic spending remains below historical levels, although it improved sequentially during the quarter.

Diagnostics: Strong underlying growth obscured by respiratory declines

Diagnostics reported 17% sales growth, largely reflecting the effect of acquisitions. Core revenue increased only 0.5%, but growth excluding respiratory testing was 7%.

Clinical Diagnostics grew mid-single digits. Leica Biosystems continued to see momentum in digital pathology and advanced staining, while Beckman Coulter Diagnostics delivered its strongest core-growth quarter in more than two years. Management attributed Beckman’s improvement to new product introductions, including the DxI 9000, and easing headwinds from Chinese healthcare policy changes.

Cepheid’s non-respiratory molecular diagnostics business grew low double digits, led by group A strep, virology, and sexual-health assays. That growth reinforces the distinction between Cepheid’s underlying testing franchise and the volatile respiratory-testing business.

Profitability and Margins

GAAP diluted EPS from continuing operations rose 34.5% to $1.71. However, the GAAP comparison benefited substantially from discrete tax items. Danaher recorded $263M of net discrete tax benefits, primarily from the release of reserves for uncertain tax positions following audit settlements.

Adjusted diluted EPS, which excludes those discrete tax benefits as well as acquisition-related intangible amortization and other items, rose 11.5% to $2.11. The adjusted result provides a clearer view of the quarter’s underlying earnings progression, although it also excludes $513M of pretax acquisition-related intangible amortization, an expense that will continue until acquired intangible assets are fully amortized.

Adjusted operating profit margin expanded 110 basis points to 29.0%, ahead of management’s expectations. Management attributed the improvement primarily to operational execution, with a modest contribution from tariff refunds received during the quarter.

Gross margin was 58.5%, while GAAP operating profit increased to $1.245B from $1.154B. Interest expense rose to $135M from $67M in the prior-year quarter, an important offset to operating earnings growth as Danaher carries higher financing costs.

Demand, Customers and Pricing

Demand trends improved across most of Danaher’s end markets, though the recovery remains uneven.

High-growth markets increased approximately 10%, with China up high single digits across all three segments. Biotechnology and Life Sciences benefited from healthier funding and investment levels in China, while Diagnostics moved beyond the most significant effects of earlier healthcare policy changes.

Developed-market core revenue was flat. Western Europe grew mid-single digits, but North America declined low single digits, primarily because of lower respiratory testing revenue.

Management continues to frame bioprocessing as a long-term high-single-digit growth business. Its confidence rests on commercial production activity, a pipeline of new programs, more complex modalities, biosimilars, and a growing number of monoclonal antibodies entering the market. The company also sees U.S. reshoring as an eventual growth opportunity, but management said the larger greenfield projects are still in planning stages and are more likely to affect results beginning in 2028 rather than 2027.

Danaher also highlighted early demand for AI-enabled laboratory automation and workflow solutions. Management said AI-related orders and revenue are not material today, though it is seeing modest benefits and growing customer interest. The company’s first AI-powered autonomous lab at Abcam is intended to demonstrate an integrated workflow combining AI, robotics, automation, consumables, software, and analytical instruments. Management said the system has the potential to accelerate reagent discovery, but this remains an early-stage initiative rather than a meaningful current revenue driver.

What is Danaher’s guidance for Q4 and full-year 2026?

For the fourth quarter of 2026, Danaher expects core revenue growth excluding respiratory testing of 4.0% to 5.0%. Respiratory testing is expected to be an approximately 150-basis-point headwind, resulting in total company core revenue growth of approximately 3.0%.

Segment expectations for the fourth quarter are:

• ·Biotechnology: Mid-single-digit core growth
• ·Life Sciences: 4.0% to 5.0% core growth
• ·Diagnostics: Core revenue up slightly
• ·Total company: Approximately 3.0% core revenue growth
• ·Adjusted operating profit margin: Approximately 29.5%

Danaher raised its full-year adjusted diluted EPS guidance to $8.57 to $8.62, from a prior range of $8.45 to $8.60. The updated outlook reflects third-quarter outperformance and implies double-digit adjusted EPS growth for the year.

Management did not provide formal 2027 guidance, but said 4% to 5% core revenue growth excluding respiratory testing is the appropriate starting point based on current market conditions. It plans to provide a more detailed outlook in January.

Management is using approximately $1.5B of respiratory testing revenue as its planning assumption for both 2026 and the initial 2027 framework. That figure assumes a more typical flu season, though management noted that respiratory demand can create a several-hundred-million-dollar range of variability around that level.

Balance Sheet, Cash Flow and Capital

Danaher generated $1.9B of operating cash flow and $1.6B of free cash flow during the quarter. Through the first nine months of 2026, operating cash flow reached $4.7B and free cash flow totaled $4.0B.

Free cash flow increased 19% in the quarter, exceeding the growth rate in adjusted EPS. The year-to-date free-cash-flow-to-net-income conversion ratio was 128%, underscoring the company’s ability to translate reported earnings into cash.

Capital deployment remains focused on acquisitions. Leica Biosystems closed its acquisition of StatLab early in the fourth quarter, adding pathology workflow capabilities. Masimo, acquired earlier in 2026, contributed high-single-digit revenue growth in its first full quarter within Danaher. Management said Masimo’s integration is progressing well, with cost-savings and commercial-synergy opportunities under development.

Investing cash outflows totaled $10.7B through the first nine months of the year, while financing activities provided $7.1B. Higher interest expense remains a factor investors should monitor as Danaher integrates recent acquisitions and allocates capital to additional opportunities.

What Investors Should Watch

1. Bioprocessing order conversion

Mid-teens bioprocessing order growth is the clearest operating sign of improving market conditions. Investors should watch whether strong orders in upstream consumables, resins, and equipment translate into revenue acceleration during 2027.

2. Respiratory testing normalization

Respiratory testing remains a major variable in reported growth. Management’s $1.5B planning assumption for 2026 and 2027 offers a baseline, but flu-season severity can move revenue by several hundred million dollars.

3. Diagnostics growth excluding respiratory revenue

Diagnostics grew 7% excluding respiratory testing, supported by Beckman Coulter, Leica Biosystems, and Cepheid’s non-respiratory assays. Sustaining that growth would validate the segment’s improvement after earlier China-related pressure.

4. Commercial execution and cross-selling

Management’s central strategic objective is more consistent share gain through coordinated customer engagement across operating companies. Investors should look for evidence that the identified revenue opportunities convert into recurring growth, rather than remaining pipeline potential.

5. Margin durability and acquisition integration

Adjusted operating margin expanded to 29.0% and is expected to reach approximately 29.5% in the fourth quarter. Future margin performance will depend on operating execution, the fade of tariff-related benefits, acquisition integration, and the effect of higher interest expense.

AlgovestIQ Takeaway

Danaher’s third quarter offered evidence that its underlying businesses are improving. Core growth excluding respiratory testing accelerated to 5.5%, bioprocessing orders grew in the mid-teens, and Diagnostics posted 7% underlying growth despite the drag from respiratory testing.

The adjusted earnings result was more representative of operating performance than the 34.5% increase in GAAP EPS, which benefited from a $263M discrete tax gain. Still, adjusted EPS growth of 11.5% and a 110-basis-point increase in adjusted operating margin demonstrate that Danaher is converting its gradual demand recovery into stronger profitability.

The central investment question is whether the company can turn improving end markets and its broader commercial strategy into sustained growth above the 4% to 5% range management currently views as the starting point for 2027. Bioprocessing order growth, recovery in academic and biotech spending, and Diagnostics execution provide potential support.

The case would strengthen if orders continue to convert into higher revenue growth, Diagnostics sustains its non-respiratory momentum, and management demonstrates measurable share gains from connected selling. It would weaken if respiratory volatility remains a larger drag than expected, bioprocessing orders fail to convert on schedule, or the company’s strategic initiatives produce pipeline opportunities without a corresponding improvement in reported organic growth.